SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon moves up on launching Yesafili in United States

03 Aug 2026 Evaluate

Biocon is currently trading at Rs. 426.60, up by 0.95 points or 0.22% from its previous closing of Rs. 425.65 on the BSE.

The scrip opened at Rs. 432.00 and has touched a high and low of Rs. 432.00 and Rs. 423.65 respectively. So far 14927 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 447.00 on 16-Jul-2026 and a 52 week low of Rs. 331.00 on 11-Aug-2025.

Last one week high and low of the scrip stood at Rs. 439.80 and Rs. 421.65 respectively. The current market cap of the company is Rs. 69,522.75 crore.

The promoters holding in the company stood at 44.68%, while Institutions and Non-Institutions held 31.52% and 23.80% respectively.

Biocon has commercially launched Yesafili (aflibercept-jbvf) in the United States. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation by the U.S. Food and Drug Administration in May 2024, allowing substitution at the pharmacy level in accordance with state laws.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

425.15 2.15 (0.51%)
04-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1960.00
Dr. Reddys Labs. 1160.65
Cipla 1450.00
Lupin 2376.00
Zydus Lifesciences 1118.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: